BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, December 18, 2025
Home » Topics » Science

Science
Science RSS Feed RSS

Patient-derived antibody activates innate immune system

May 18, 2022
By Anette Breindl
A target-agnostic search has yielded a patient-derived antibody that activated the innate immune system, researchers from Atreca and Stanford University reported in the May 4,2022, issue of the Proceedings of the National Academy of Sciences.
Read More
Aging illustration

Multiple aging hallmarks show up as epigenetic changes

May 16, 2022
By Anette Breindl
Age is the biggest risk factor for just about every common disease in high-income countries, which suggests that slowing down cellular aging would have massive effects on individual and public health. Delaying the average onset of Alzheimer’s disease by five years, for example, would roughly halve its prevalence. But in practice, there are no approved anti-aging medications.
Read More
Cancer cell and DNA

Diabetic foot ulcers hold clues to tumor suppression

May 16, 2022
By W. Todd Penberthy
New genomic research has increased the understanding of surprising links between diabetic foot ulcers and carcinomas.
Read More
Assembling a draft Human Cell Atlas

Across body parts, ‘parts list’ gives insights into the lives of a cell

May 12, 2022
By Anette Breindl
“People often think about the genome as the blueprint of the organism, but that’s not really correct,” Steven Quake told reporters at a Science press briefing earlier this week. “The genome is more of a parts list, because every cell type uses different parts.” Quake is president of the Chan Zuckerberg Biohub Network, and professor of bioengineering and applied physics at Stanford University.
Read More
Back pain

Inflammation is key to preventing chronic pain, study finds

May 11, 2022
By Anette Breindl
More than 10% of Americans suffer from chronic pain, and how to prevent acute pain from turning chronic has been a critical question in pain research. But according to a study published in the May 11, 2022, issue of Science Translational Medicine, that approach has it backwards. In several animal models of pain, the resolution of acute pain was an active process. Chronic pain happened when those active processes failed to occur.
Read More
Glucose testing

Type 2 diabetes getting precision medicine makeover

May 11, 2022
By Nuala Moran
Type 2 diabetes is known to involve many different underlying mechanisms, but the considerable heterogeneity in the phenotype is mostly ignored in how it is treated. Now, researchers at University of Dundee, U.K., have developed a method for visualizing this heterogeneity and shown how the risks of complications, such as chronic kidney disease or peripheral neuropathy, differ by phenotypes.
Read More
Breast cancer illustration
ESMO Breast Cancer 2022

Taking aim at tumor metabolism, while taming toxicity

May 10, 2022
By Anette Breindl
There are 40 years of history behind the development of phosphoinositide 3-kinase (PI3K) inhibitors, Rebecca Dent told her audience at ESMO Breast Cancer 2022. And there have been success stories. There are five FDA-approved PI3K inhibitors in several cancer types, and in April, the FDA approved Vijoice (alpelisib; Novartis AG) for PIK3CA-related overgrowth spectrum, a rare disorder resulting from germline mutations of PIK3CA.
Read More
Fallopian tubes, ovaries and uterus

Comparative study focuses lens of human reproductive aging

May 10, 2022
By Anette Breindl
A comparison of seven nonhuman primate species has found both similarities and differences among the effects of age on female reproduction.
Read More
Silhouette made of crumpled paper illustrating depression

Proline links gut microbiome to depression

May 9, 2022
By Nuala Moran
If it is now acknowledged the gut microbiota plays a role in the pathophysiology of depression, the specific biochemical mechanisms underlying this connection are hard to unpick and poorly understood.
Read More
Breast cancer illustration
ESMO Breast Cancer 2022

Taking aim at tumor metabolism, while taming toxicity

May 6, 2022
By Anette Breindl
There are 40 years of history behind the development of phosphoinositide 3-kinase (PI3K) inhibitors, Rebecca Dent told her audience at ESMO Breast Cancer 2022. And there have been success stories. There are five FDA-approved PI3K inhibitors in several cancer types, and in April, the FDA approved Vijoice (alpelisib; Novartis AG) for PIK3CA-related overgrowth spectrum, a rare disorder resulting from germline mutations of PIK3CA.
Read More
Previous 1 2 … 54 55 56 57 58 59 60 61 62 … 188 189 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 18, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 18, 2025.
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • Illustration of brain with electrical activity background

    ABS-1230 controls seizures in KCNT1-driven severe epilepsy

    BioWorld Science
    Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
  • Brain and encephalography

    DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

    BioWorld
    Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing